Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
May 26th, 2026
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases. The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday. “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Dan Skovronsky, Lilly’s chief scientific and product officer, said in a statement. Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers.
Duration:3:56
Nasty Texas Republican Runoff Comes to a Head Today
Duration:2:59
Ferrari's First EV, the Luce, Gets Brutal Reviews
Duration:3:07
Fed’s Case for Cutting Rates ‘Very, Very Weak,' Bill Dudley Says
Duration:5:12
Israel Seeks Deal That Eliminates Nuclear Danger From Iran
Duration:3:47
US Told to Evacuate Citizens From Kyiv
Daybreak: Europe
Duration:2:58
WHO Warns Ebola Epidemic Is ‘Outpacing’ Response
Daybreak: Europe
Duration:1:39
Qualcomm to Supply Chips to TikTok Owner ByteDance
Technology
Duration:3:46
UBS Raises Micron to Street-High Target
Available on:
Listen onApple TVListen onRokuListen onSamsung TVListen onFire TVListen onAndroid TVListen onRakuten TVListen onHaystack NewsWatch BTV in your area:
Channel FinderСхожі новини
